Developer docs
API playgroundTry for free, no card

Search company profiles

Polbionica

Full company profile

uuid0063n9i

Namestring
Polbionica
Legal namestring
Polbionica
Websiteurl
polbionica.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Polbionica is a privately held Polish research center and biotech company founded in 2019 and headquartered in Zielona Góra, with a secondary office in Warsaw. The company specializes in 3D bioprinting and biofabrication, developing a vertically integrated ecosystem of proprietary bioinks (TintBionic, Printiss, CleanCure), a photo-curing platform (BionicCure UV-Vis lamp), a dynamic bioreactor system (ResearchLine 3D Flow & Culture), recombinant structural proteins (p-SE17, p-RE15), and custom 3D bioprinting services. Manufacturing is conducted under ISO 13485 quality management, supporting batch-to-batch reproducibility required by research and clinical customers.

The company's flagship program is the Bionic Pancreas-ATMP — described as the world's first functional organ bioprinted from living cells, with full vascularization and physiological insulin/glucagon secretion capability — targeting type 1 diabetes and chronic pancreatitis. Preclinical studies have been completed and the company is preparing for clinical trials, positioning the asset as a future therapeutic revenue stream under ATMP regulatory pathways. The platform also supports 3D bioprinted liver tissue models and personalized tissue constructs for drug testing and preclinical research applications.

Commercially, Polbionica operates a B2B sales-led model selling bioinks and biomaterials (one-time consumables), laboratory capital equipment (bioreactors, UV-Vis lamps), and bespoke 3D bioprinting services directly through its company website to academic researchers, pharmaceutical preclinical teams, and clinicians. The horizontal segmentation across regenerative medicine, drug development, and clinical end-markets diversifies exposure but no named customer logos or revenue figures are publicly disclosed. Non-dilutive funding has come via two European Commission Seals of Excellence (Horizon 2020 SME Instrument in 2020 and Horizon Europe EIC Accelerator in 2023), while the AuRes automatic resuscitator signals broader medtech ambition beyond bioprinting.

Short descriptiontext

Polbionica is a Polish 3D bioprinting biotech that develops proprietary bioinks, a bioreactor platform, and bioprinting services for researchers, pharmaceutical preclinical teams, and clinicians, with its flagship Bionic Pancreas-ATMP advancing toward clinical trials for type 1 diabetes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWarszawa, Poland
HQ citystring
Warszawa
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D bioprinting solutions, bioink manufacturing, tissue engineering products, bioreactor equipment, regenerative medicine therapeutics
Industry2 codes
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
  • Medicinal Chemicals & Botanical Products2833
Product category
3D Bioprinting & Tissue Engineering
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Bioinks and Biomaterials Sales
TypeOne Time License
Description

Polbionica manufactures and sells a comprehensive portfolio of proprietary bioinks and biomaterials including TintBionic, Printiss, CleanCure, LAP photoinitiator, and recombinant proteins (p-SE17, p-RE15). Products are available through the company website catalog with per-unit pricing. ISO 13485 certified manufacturing supports product quality and reproducibility.

polbionica.com
2Laboratory Devices Sales
TypeHardware Sales
Description

Sale of laboratory equipment including the ResearchLine Bioreactor 3D Flow & Culture and BionicCure UV-Vis lamps. These are capital equipment purchases for research laboratories and institutions.

polbionica.com
33D Bioprinting Services
TypeProfessional Services
Description

Specialized bioprinting services including 3D bioprinted organoids and tissue models, cellular scaffold bioprinting, and 3D bioprinting consulting services. Services target researchers and clinicians requiring custom bioprinting solutions.

polbionica.com
4Bionic Pancreas-ATMP Therapeutic Development
TypeLicensing Royalties
Description

Following successful preclinical studies, the company is preparing for clinical trials for the Bionic Pancreas-ATMP as a novel therapeutic for type 1 diabetes and chronic pancreatitis. This represents a future therapeutic revenue stream.

polbionica.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1TintBionic®
Description

Advanced biomaterials product line for biofabrication and 3D bioprinting, including GELMA 50, GELMA 80, ALGMA, HAMA, CHIMA, and GELMA-G variants.

polbionica.com
+6 more records
Core offering1 text field

Polbionica develops and manufactures a vertically integrated ecosystem for 3D bioprinting, including proprietary bioink lines (TintBionic, CleanCure, Printiss), laboratory devices (ResearchLine bioreactor, BionicCure UV-Vis lamp, LAP photoinitiator), recombinant proteins (p-SE17, p-RE15), and 3D bioprinting services for tissue/organoid fabrication. Its flagship program is the Bionic Pancreas-ATMP, a fully vascularized bioprinted organ targeting type 1 diabetes and chronic pancreatitis. Products are manufactured under ISO 13485 quality management for researchers, clinicians, and pharmaceutical customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Full vascularization and physiological insulin and glucagon secretion demonstrated in Bionic Pancreas-ATMP preclinical studies
+1 more record
Product and service1 record
1TintBionic Bioink Line
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

German company developing multi-organ-on-chip platforms using tissue engineering approaches. Adjacent to Polbionica's bioreactor and 3D tissue model offerings, with overlapping customer base in preclinical drug testing applications.

TypeDirect peer
Description

Israel-based regenerative medicine company developing bioinks and tissue products from recombinant human collagen. Direct competitor in tissue-specific bioinks for 3D bioprinting and biofabrication applications.

TypeDirect peer
Description

Swiss manufacturer of bioprinters and biofabrication platforms for tissue engineering and regenerative medicine. Comparable to Polbionica's hardware offering (ResearchLine bioreactor, BionicCure UV-Vis lamp) in providing specialized bioprinting equipment to research labs.

TypeDirect peer
Description

BICO (parent of CELLINK) is the dominant commercial player in bioprinters, bioinks, and lab automation for 3D cell culture. Directly competes with Polbionica's bioinks and bioprinting equipment, but at substantially larger scale across broader life science applications.

5Aspect Biosystems
TypeDirect peer
Description

Canadian bioprinting company developing physiologically relevant tissues for therapeutic and drug discovery applications. Directly comparable in combining proprietary bioprinting technology with a pipeline of tissue therapeutics, including endocrinology-focused programs.

6Advanced BioMatrix
TypeDirect peer
Description

Specialized bioink and biomaterials supplier for 3D bioprinting and tissue engineering research. Directly competes with Polbionica's TintBionic and Printiss product lines in the research bioink catalog market.

TypeEmerging player
Description

Japanese regenerative medicine company using 3D bioprinting to produce cellular constructs for clinical applications. Comparable in bridging proprietary biofabrication technology with therapeutic tissue development, though focused on different tissue types.

TypeEmerging player
Description

India-based biotech developing 3D bioprinted tissues and organoids, including cornea and liver tissues. Comparable emerging player combining bioink development with therapeutic tissue programs targeting specific organ indications.

TypeDirect peer
Description

Pioneer in 3D bioprinted human tissues for preclinical drug discovery and therapeutic applications. Closest direct peer to Polbionica in targeting functional tissue therapeutics and disease models using bioprinting.

TypeEmerging player
Description

Biofabrication company leveraging tissue engineering and bio-based materials, initially focused on sustainable materials with emerging therapeutic applications. Comparable in applying biofabrication technology beyond pure research tools toward commercial therapeutic products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polbionica

3D Bioprinting & Tissue Engineeringpolbionica.com

Polbionica is a Polish 3D bioprinting biotech that develops proprietary bioinks, a bioreactor platform, and bioprinting services for researchers, pharmaceutical preclinical teams, and clinicians, with its flagship Bionic Pancreas-ATMP advancing toward clinical trials for type 1 diabetes.

What Polbionica does

Polbionica is a privately held Polish research center and biotech company founded in 2019 and headquartered in Zielona Góra, with a secondary office in Warsaw. The company specializes in 3D bioprinting and biofabrication, developing a vertically integrated ecosystem of proprietary bioinks (TintBionic, Printiss, CleanCure), a photo-curing platform (BionicCure UV-Vis lamp), a dynamic bioreactor system (ResearchLine 3D Flow & Culture), recombinant structural proteins (p-SE17, p-RE15), and custom 3D bioprinting services. Manufacturing is conducted under ISO 13485 quality management, supporting batch-to-batch reproducibility required by research and clinical customers.

The company's flagship program is the Bionic Pancreas-ATMP — described as the world's first functional organ bioprinted from living cells, with full vascularization and physiological insulin/glucagon secretion capability — targeting type 1 diabetes and chronic pancreatitis. Preclinical studies have been completed and the company is preparing for clinical trials, positioning the asset as a future therapeutic revenue stream under ATMP regulatory pathways. The platform also supports 3D bioprinted liver tissue models and personalized tissue constructs for drug testing and preclinical research applications.

Commercially, Polbionica operates a B2B sales-led model selling bioinks and biomaterials (one-time consumables), laboratory capital equipment (bioreactors, UV-Vis lamps), and bespoke 3D bioprinting services directly through its company website to academic researchers, pharmaceutical preclinical teams, and clinicians. The horizontal segmentation across regenerative medicine, drug development, and clinical end-markets diversifies exposure but no named customer logos or revenue figures are publicly disclosed. Non-dilutive funding has come via two European Commission Seals of Excellence (Horizon 2020 SME Instrument in 2020 and Horizon Europe EIC Accelerator in 2023), while the AuRes automatic resuscitator signals broader medtech ambition beyond bioprinting.

Polbionica firmographics

Firmographics
Name
Polbionica
Legal name
Polbionica
Website
https://polbionica.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Polbionica is a Polish 3D bioprinting biotech that develops proprietary bioinks, a bioreactor platform, and bioprinting services for researchers, pharmaceutical preclinical teams, and clinicians, with its flagship Bionic Pancreas-ATMP advancing toward clinical trials for type 1 diabetes.
Ownership category
akta.pro rank

Polbionica industry classification

Industry
Product category
3D Bioprinting & Tissue Engineering
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

Keywords

  • 3D bioprinting solutions
  • Bioink manufacturing
  • Tissue engineering products
  • Bioreactor equipment
  • Regenerative medicine therapeutics

Where Polbionica is headquartered

Location

Headquarters

HQ city
Warszawa
HQ country
Poland
HQ region
Europe

Offices2 records

Markets served

Polbionica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Bioinks and Biomaterials Sales: Polbionica manufactures and sells a comprehensive portfolio of proprietary bioinks and biomaterials including TintBionic, Printiss, CleanCure, LAP photoinitiator, and recombinant proteins (p-SE17, p-RE15). Products are available through the company website catalog with per-unit pricing. ISO 13485 certified manufacturing supports product quality and reproducibility.
  2. Laboratory Devices Sales: Sale of laboratory equipment including the ResearchLine Bioreactor 3D Flow & Culture and BionicCure UV-Vis lamps. These are capital equipment purchases for research laboratories and institutions.
  3. 3D Bioprinting Services: Specialized bioprinting services including 3D bioprinted organoids and tissue models, cellular scaffold bioprinting, and 3D bioprinting consulting services. Services target researchers and clinicians requiring custom bioprinting solutions.
  4. Bionic Pancreas-ATMP Therapeutic Development: Following successful preclinical studies, the company is preparing for clinical trials for the Bionic Pancreas-ATMP as a novel therapeutic for type 1 diabetes and chronic pancreatitis. This represents a future therapeutic revenue stream.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Polbionica product offering

Product offering

Core offering

Polbionica develops and manufactures a vertically integrated ecosystem for 3D bioprinting, including proprietary bioink lines (TintBionic, CleanCure, Printiss), laboratory devices (ResearchLine bioreactor, BionicCure UV-Vis lamp, LAP photoinitiator), recombinant proteins (p-SE17, p-RE15), and 3D bioprinting services for tissue/organoid fabrication. Its flagship program is the Bionic Pancreas-ATMP, a fully vascularized bioprinted organ targeting type 1 diabetes and chronic pancreatitis. Products are manufactured under ISO 13485 quality management for researchers, clinicians, and pharmaceutical customers.

Differentiator

Problem solved

Functional benefit

Brands

  • TintBionic®: Advanced biomaterials product line for biofabrication and 3D bioprinting, including GELMA 50, GELMA 80, ALGMA, HAMA, CHIMA, and GELMA-G variants.
  • Printiss®
  • CleanCure™
  • BionicCure™
  • ResearchLine™
  • Bionic Pancreas-ATMP®
  • Hybrid Recombinant Proteins

Products and services

  • TintBionic Bioink Line

Quantifiable outcome

  • Full vascularization and physiological insulin and glucagon secretion demonstrated in Bionic Pancreas-ATMP preclinical studies
  • +1 more outcomes

Companies that use Polbionica

Customer profile

Segments3 records

Ideal customer profiles3 records

Polbionica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Polbionica partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Polbionica competitors and assessment

Company assessment

Emerging players

  • TissUse: German company developing multi-organ-on-chip platforms using tissue engineering approaches. Adjacent to Polbionica's bioreactor and 3D tissue model offerings, with overlapping customer base in preclinical drug testing applications.
  • Cyfuse Biomedical: Japanese regenerative medicine company using 3D bioprinting to produce cellular constructs for clinical applications. Comparable in bridging proprietary biofabrication technology with therapeutic tissue development, though focused on different tissue types.
  • Pandorum Technologies: India-based biotech developing 3D bioprinted tissues and organoids, including cornea and liver tissues. Comparable emerging player combining bioink development with therapeutic tissue programs targeting specific organ indications.
  • Modern Meadow: Biofabrication company leveraging tissue engineering and bio-based materials, initially focused on sustainable materials with emerging therapeutic applications. Comparable in applying biofabrication technology beyond pure research tools toward commercial therapeutic products.

Direct peers

  • CollPlant Biotechnologies: Israel-based regenerative medicine company developing bioinks and tissue products from recombinant human collagen. Direct competitor in tissue-specific bioinks for 3D bioprinting and biofabrication applications.
  • RegenHU: Swiss manufacturer of bioprinters and biofabrication platforms for tissue engineering and regenerative medicine. Comparable to Polbionica's hardware offering (ResearchLine bioreactor, BionicCure UV-Vis lamp) in providing specialized bioprinting equipment to research labs.
  • BICO (CELLINK): BICO (parent of CELLINK) is the dominant commercial player in bioprinters, bioinks, and lab automation for 3D cell culture. Directly competes with Polbionica's bioinks and bioprinting equipment, but at substantially larger scale across broader life science applications.
  • Aspect Biosystems: Canadian bioprinting company developing physiologically relevant tissues for therapeutic and drug discovery applications. Directly comparable in combining proprietary bioprinting technology with a pipeline of tissue therapeutics, including endocrinology-focused programs.
  • Advanced BioMatrix: Specialized bioink and biomaterials supplier for 3D bioprinting and tissue engineering research. Directly competes with Polbionica's TintBionic and Printiss product lines in the research bioink catalog market.
  • Organovo: Pioneer in 3D bioprinted human tissues for preclinical drug discovery and therapeutic applications. Closest direct peer to Polbionica in targeting functional tissue therapeutics and disease models using bioprinting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Polbionica social profiles

Digital presence

Polbionica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polbionica leadership team

Management profile

Number of profiles

Profiles3 records

Polbionica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polbionica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polbionica

What does Polbionica do?

Polbionica develops and manufactures a vertically integrated ecosystem for 3D bioprinting, including proprietary bioink lines (TintBionic, CleanCure, Printiss), laboratory devices (ResearchLine bioreactor, BionicCure UV-Vis lamp, LAP photoinitiator), recombinant proteins (p-SE17, p-RE15), and 3D bioprinting services for tissue/organoid fabrication. Its flagship program is the Bionic Pancreas-ATMP, a fully vascularized bioprinted organ targeting type 1 diabetes and chronic pancreatitis. Products are manufactured under ISO 13485 quality management for researchers, clinicians, and pharmaceutical customers.

Is Polbionica a public or private company?

Polbionica is a private company. It is classified as unknown and is currently operating.

When was Polbionica founded?

Polbionica was founded in 2019. It employs 11 to 50 people.

Where is Polbionica based?

Polbionica is headquartered in Warszawa, Poland, in the Europe region.

How does Polbionica make money?

Four revenue lines are on record. Bioinks and Biomaterials Sales are the primary driver. The others are laboratory Devices Sales, 3D Bioprinting Services and bionic Pancreas-ATMP Therapeutic Development.

Who are Polbionica's main competitors?

Emerging players on record are TissUse, Cyfuse Biomedical, Pandorum Technologies and Modern Meadow. Direct peers are CollPlant Biotechnologies, RegenHU, BICO (CELLINK), Aspect Biosystems, Advanced BioMatrix and Organovo.

Does Polbionica have an API?

No public API is recorded for Polbionica.

What industry is Polbionica in?

Polbionica's product category is 3D Bioprinting & Tissue Engineering. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales